Management of angina and the role of Ranolazine in the context of the NICE guidelines
Managing chronic stable angina pectoris continues to represent a challenge to the practicing physician. Novel anti-angina agents have been incorporated to our therapeutic arsenal in recent years. Ranolazine is one of such agents with novel mechanisms of actions. This programme focuses on the indications, contraindications and practical use of this agent in clinical practice. General practitioners, hospital consultants and clinical-academics contribute their expert views and practical suggestions in this online educational programme.
Related articles
01/02/2017 - Recurrent or persistent angina after coronary artery revascularisation and stent implantation - Prof Juan Carlos Kaski, St George's, University of London, UK
08/22/2016 - Non- Pharmacological management of refractory Angina - Prof Juan Carlos Kaski, St George's, University of London, UK
06/27/2016 - Ranolazine for management of microvascular angina - Prof Juan Carlos Kaski, St George's, University of London, UK
11/10/2015 - Diagnosing angina: key differences between men and women - Dr Noel Bairey-Merz, Director, Barbra Streisand Women’s Heart Center and Preventive Cardiac Center; Professor of Medicine, Heart Institute, Cedars-Sinai Medical Center and UCLA, USA.
09/02/2015 - Long QT syndrome and epilepsy -
06/26/2015 - Clinical cases where an indication for ranolazine may exist - Dr Rajan Sharma, St Geroge's University of London
Leave a Reply
You must be logged in to post a comment.